8-K
filed May 5, 2023, 7:59 PM ET
ticker MRNA
CIK 0001682852
other material
confidence high
sentiment neutral
materiality 0.15
Moderna Stockholders Elect Three Class II Directors and Approve Executive Compensation at 2023 Annual Meeting
Moderna, Inc.
- Elected Stephen Berenson (226.6M for, 64.2M withheld), Sandra Horning (281.8M for, 8.9M withheld), and Paul Sagan (219.0M for, 71.7M withheld) as Class II directors.
- Advisory vote on named executive officer compensation approved with 254.1M for, 34.9M against, and 1.6M abstentions.
- Ratification of Ernst & Young as independent auditor for 2023 approved with 352.0M for, 3.9M against, and 0.2M abstentions.
- Shareholder proposal requesting report on feasibility of transferring intellectual property defeated: 21.4M for, 268.0M against, 1.3M abstain.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Moderna, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2023-05-03 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-03
Exact text from the filing
Proposal 3. Ratification of appointment of independent registered public accounting firm. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, with the votes cast as follows:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2023-05-03 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-03
Exact text from the filing
Proposal 2. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Moderna, Inc. shareholders rejected Shareholder proposal requesting a report on feasibility of transferring intellectual property at the 2023-05-03 meeting.
- Outcome
- failed
- Meeting
- 2023-05-03
Exact text from the filing
Proposal 4. Shareholder proposal requesting a report on feasibility of transferring intellectual property.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Moderna, Inc. shareholders approved Election of Class II directors at the 2023-05-03 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-03
Exact text from the filing
Proposal 1. Election of directors. By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as Class II directors for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal:
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.